Autolus Therapeutics (NASDAQ:AUTL) delivers shareholders stellar 266% return over 1 year, surging 18% in the last week alone

AUTOLUS THERAPEUTICS LTD -5.82%

AUTOLUS THERAPEUTICS LTD

AUTL

5.02

-5.82%

The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But if you pick the right stock, you can make a lot more than 100%. For example, the Autolus Therapeutics plc (NASDAQ:AUTL) share price had more than doubled in just one year - up 266%. Also pleasing for shareholders was the 185% gain in the last three months. On the other hand, longer term shareholders have had a tougher run, with the stock falling 26% in three years.

Since it's been a strong week for Autolus Therapeutics shareholders, let's have a look at trend of the longer term fundamentals.

See our latest analysis for Autolus Therapeutics

Autolus Therapeutics isn't currently profitable, so most analysts would look to revenue growth to get an idea of how fast the underlying business is growing. When a company doesn't make profits, we'd generally expect to see good revenue growth. That's because fast revenue growth can be easily extrapolated to forecast profits, often of considerable size.

Autolus Therapeutics grew its revenue by 103% last year. That's stonking growth even when compared to other loss-making stocks. Meanwhile, the market has paid attention, sending the share price soaring 266% in response. That sort of revenue growth is bound to attract attention, even if the company doesn't turn a profit. Given the positive sentiment around the stock we're cautious, but there's no doubt its worth watching.

The company's revenue and earnings (over time) are depicted in the image below (click to see the exact numbers).

earnings-and-revenue-growth
NasdaqGS:AUTL Earnings and Revenue Growth December 29th 2023

You can see how its balance sheet has strengthened (or weakened) over time in this free interactive graphic.

A Different Perspective

It's good to see that Autolus Therapeutics has rewarded shareholders with a total shareholder return of 266% in the last twelve months. There's no doubt those recent returns are much better than the TSR loss of 13% per year over five years. The long term loss makes us cautious, but the short term TSR gain certainly hints at a brighter future. While it is well worth considering the different impacts that market conditions can have on the share price, there are other factors that are even more important. Consider for instance, the ever-present spectre of investment risk. We've identified 2 warning signs with Autolus Therapeutics , and understanding them should be part of your investment process.

But note: Autolus Therapeutics may not be the best stock to buy. So take a peek at this free list of interesting companies with past earnings growth (and further growth forecast).

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges.

Every question you ask will be answered
Scan the QR code to contact us
whatsapp
Also you can contact us via